|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126 JPY | +1.61% |
|
+1.61% | -6.67% |
| 04-01 | Chiome Bioscience Cancels License Agreements with ADC Therapeutics | MT |
| 02-13 | Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited | CI |
Chiome Bioscience Inc. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was JPY 433.69 million compared to JPY 541.69 million a year ago. Net loss was JPY 1,027.56 million compared to JPY 842.79 million a year ago.
Basic loss per share from continuing operations was JPY 23.87 compared to JPY 20.94 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -6.67% | 45.11M | |
| +22.56% | 46.4B | |
| -1.51% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +10.13% | 26.01B | |
| -20.44% | 19.52B | |
| +26.45% | 12.43B | |
| -0.14% | 12.18B | |
| -0.47% | 12.13B |
CHIOME BIOSCIENCE INC. 
